Dataset Information

Baseline Characteristics of the VANISH Cohort.

ABSTRACT: Background: The VANISH trial (Valsartan for Attenuating Disease Evolution in Early Sarcomeric Hypertrophic Cardiomyopathy) targeted young sarcomeric gene mutation carriers with early-stage hypertrophic cardiomyopathy (HCM) to test whether valsartan can modify disease progression. We describe the baseline characteristics of the VANISH cohort and compare to previous trials evaluating angiotensin receptor blockers.

Methods: Applying a randomized, double-blinded, placebo-controlled design, 178 participants with nonobstructive HCM (age, 23.3±10.1 years; 61% men) were randomized in the primary cohort and 34 (age, 16.5±4.9 years; 50% men) in the exploratory cohort of sarcomeric mutation carriers without left ventricular hypertrophy.

Results: In the primary cohort, maximal left ventricular wall thickness was 17±4 mm for adults and Z score 7.0±4.5 for children. Nineteen percent had late gadolinium enhancement on cardiac magnetic resonance. Mean peak oxygen consumption was 33 mL/kg per minute, and 92% of participants were New York Heart Association functional class I. New York Heart Association class II was associated with older age, MYH7 variants, and more prominent imaging abnormalities. Six previous trials of angiotensin receptor blockers in HCM enrolled a median of 24 patients (range, 19-133) with mean age of 51.2 years; 42% of patients were in New York Heart Association class ?II, and sarcomeric mutations were not required.

Conclusions: The VANISH cohort is much larger, younger, less heterogeneous, and has less advanced disease than prior angiotensin receptor blocker trials in HCM. Participants had relatively normal functional capacity and mild HCM features. New York Heart Association functional class II symptoms were associated with older age, more prominent imaging abnormalities, and MYH7 variants, suggesting both phenotype and genotype contribute to disease manifestations.

Clinical trial registration: URL: https://www.clinicaltrials.gov. Unique identifier: NCT01912534.

SUBMITTER: Axelsson Raja A

PROVIDER: S-EPMC7219518 | biostudies-literature | 2019 Dec

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Baseline Characteristics of the VANISH Cohort.

Axelsson Raja Anna A Shi Ling L Day Sharlene M SM Russell Mark M Zahka Kenneth K Lever Harry H Colan Steven D SD Margossian Renee R Hall E Kevin EK Becker Jason J Jefferies John Lynn JL Patel Amit R AR Choudhury Lubna L Murphy Anne M AM Canter Charles C Bach Richard R Taylor Matthew M Mestroni Luisa L Wheeler Matthew T MT Benson Lee L Owens Anjali T AT Rossano Joseph J Lin Kimberly Y KY Pahl Elfriede E Pereira Alexandre C AC Bundgaard Henning H Lewis Gregory D GD Vargas Jose D JD Cirino Allison L AL McMurray John J V JJV MacRae Calum A CA Solomon Scott D SD Orav E John EJ Braunwald Eugene E Ho Carolyn Y CY

Circulation. Heart failure 20191209 12

<h4>Background</h4>The VANISH trial (Valsartan for Attenuating Disease Evolution in Early Sarcomeric Hypertrophic Cardiomyopathy) targeted young sarcomeric gene mutation carriers with early-stage hypertrophic cardiomyopathy (HCM) to test whether valsartan can modify disease progression. We describe the baseline characteristics of the VANISH cohort and compare to previous trials evaluating angiotensin receptor blockers.<h4>Methods</h4>Applying a randomized, double-blinded, placebo-controlled desi ...[more]

PMID: 31813281

Similar Datasets

Project description:PurposeThe Shenzhen ageing-related disorder cohort was designed to detect the associations of lifestyle, environmental and genetic factors with major ageing-related disorders, especially neurological and mental disorders.ParticipantsThe cohort was a community-dwelling prospective study of 9411 elderly adults aged 60 to 92 years from 51 community health service centres in Luohu district of Shenzhen, China. The baseline data were collected between 2017 and 2018, including demographics and socioeconomics, lifestyles, medical history, family history of major non-communicable chronic disease, environmental exposures, clinical analysis of blood and urine, clinical imaging measurements, anthropometric measures and neurological function and mental health assessments. Blood and urinary samples were collected at baseline. All participants will be followed for physiological and psychological disorders and updated lifestyle and environmental exposures every 5 years.Findings to dateThe mean age of the participants was 67.73 years at baseline, and 42.74% were males. The prevalences of individuals with unhealthy conditions were as follows: overweight/obesity (54.38%), hypertension (58.24%), diabetes mellitus (22.30%), dyslipidaemia (75.69%), chronic bronchitis (1.45%), myocardial infarction (0.55%), coronary heart disease (5.69%), stroke (1.10%), cancer (2.18%), arthritis (5.04%), Alzheimer's disease (0.18%), Parkinson's disease (0.23%), brain injury (5.75%), cognitive impairment (5.39%) and depression status (3.28%). The mean scores for the Lawton-Brody Activities of Daily Living Scale and the Social Support Rate Scale were 14.15 and 39.54, respectively.Future plans2000 new entrants from Luohu district will be recruited every year until 2028. The data collection is expected to be ended at the end of 2030. The data will be used to assess the causality of ageing-related disorders, especially neurological and mental disorders through integrating environmental, genetic and lifestyle factors. The data sets generated and/or analysed during the current study are not publicly available at this stage, but are available from the corresponding author on reasonable request.

Dataset Information

Baseline Characteristics of the VANISH Cohort.

Publications

Baseline Characteristics of the VANISH Cohort.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets